Randomized Trial Investigates Intranasal Oxytocin for Social Learning in Autism Spectrum Disorders

The Autism Spectrum Disorders (ASD) are complex neurodevelopmental conditions characterized by persistent deficits in social communication and interaction, alongside restricted, repetitive patterns of behavior, interests, or activities. These core social challenges significantly impact quality of life. Current therapeutic approaches primarily involve behavioral interventions, but pharmacological options directly targeting the underlying social cognitive deficits are limited and often address co-occurring symptoms rather than core ASD features. Oxytocin, a naturally occurring neuropeptide, plays a crucial role in regulating social behaviors, empathy, and trust, making it a compelling candidate for modulating social cognition in individuals with ASD. Its potential to enhance social perceptual learning, particularly face processing, is a key area of investigation, as difficulties in interpreting social cues from faces are common in ASD. This study aims to bridge this therapeutic gap by exploring oxytocin's effects in combination with a targeted intervention.